Xolair (omalizumab) - Roche, Novartis
Study on the Role of Omalizumab in Children with Severe Allergic Reactions (ChiCTR) - Oct 16, 2026 - P=N/A | N=20 | Completed | Sponsor: The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University 
New trial • Allergy • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases
https://www.chictr.org.cn/showproj.html?proj=327686
 
Oct 16, 2026
 
Prev Next